Hypoplastic left heart syndrome (HLHS) carries a high mortality. The prognostic value of echocardiographic variables at presentation and the importance of serial data are poorly explored.
H
ypoplastic left heart syndrome (HLHS) is a spectrum of congenital heart disease where the left ventricle (LV) and left-sided structures are deemed inadequate to maintain the circulation. 1 When active postnatal intervention is pursued, HLHS necessitates staged surgical palliation, culminating in a Fontan circulation.
Despite various surgical approaches at stage 1, [2] [3] [4] [5] [6] morbidity and mortality remain high as reported in different multi-institutional studies. 4 Multiple risk factors for death or heart transplant have been proposed at baseline and at follow-up. These include, among others, anatomic subtype (in particular mitral stenosis/ aortic atresia with or without coronary sinusoids), [7] [8] [9] [10] LV size, 7, 11 ascending aorta size, 9 right ventricular (RV) dysfunction, 1, [12] [13] [14] and tricuspid regurgitation. [15] [16] [17] Many of these risk factors are diagnosed by echocardiography, which is routinely used in clinical practice for initial evaluation and serial followup. Yet, the prognostic value of baseline and serial evaluation of echocardiographic parameters in HLHS remains incompletely characterized. Altmann et al 13 suggested that echocardiographic parameters at presentation and after stage 1 predict midterm mortality. However, these data, published 17 years ago, have not been evaluated in the light of changing surgical and perioperative management, 18 and other studies have not evaluated serial changes in echocardiographic parameters in relation to clinical events. 6, 14, [19] [20] [21] [22] [23] Although echocardiographic findings are only one aspect in a complex pathology with multiple variables that affect outcomes, it is a commonly used tool in patients with HLHS which conveys important information and thus may aid management. Accordingly, the objectives of this study were to (1) identify echocardiographic and clinical risk factors at time of presentation for subsequent death or heart transplantation, and (2) describe longitudinal changes in echocardiographic parameters over time and evaluate the association between changes in these parameters and mortality.
METHODS
We retrospectively analyzed serial echocardiograms obtained between 2004 and 2013 of all children diagnosed with HLHS between ages 0 and 18 years at time of study who underwent a stage-1 procedure (atrial septectomy, Damus Kaye Stansel procedure and modified Blalock-Taussig shunt or Sano RV to pulmonary artery (PA) conduit, or hybrid procedure with patent ductus arteriosus stent, atrial septal defect creation, and PA banding).The choice of stage-1 procedure was influenced by several factors including family and physician preference. Accordingly, those who died or were transplanted before stage 1 were excluded. To avoid potential confounding factors or additional morphological complexity introduced by a wide spectrum of anatomic variants, we excluded patients with ventricular septal defect, unbalanced atrioventricular septal defect, and double outlet right ventricle with mitral atresia. We also excluded patients with major extracardiac abnormalities that could independently affect the patient's outcome (eg, trisomy 18) or if their gestational age was <36 weeks or birth weight was <2.5 kg, as these are known risk factors for mortality. Patient demographics and clinical data were extracted from the medical record. The study was approved by the institutional review board at the Hospital for Sick Children. Informed consent was not required because of the retrospective nature of the study. The data, analytic methods, and study materials will be made available to other researchers for purposes of reproducing the results or replicating the procedure. The data that support the findings of this study are available from the corresponding author on reasonable request.
CLINICAL PERSPECTIVE
Hypoplastic left heart syndrome carries high morbidity and mortality. The prognostic value of echocardiographic variables at presentation and the importance of serial data are poorly explored. We undertook to perform a comprehensive, serial evaluation of widely used and available echocardiographic parameters, in the context of the clinical status, in relation to hypoplastic left heart syndrome outcomes through staged palliation. We used statistical analysis to account for each stage of palliation and related this to outcomes based on echocardiographic parameters. The major findings of our study were at presentation increased interventricular septal thickness was associated with elevated risk of transplant or death to stage 2 and stage 3, and a larger left ventricle was associated with worse transplant-free survival to stage 2. A better tricuspid valve annular planar systolic excursion z score at baseline was associated with reduced risk of transplant or death. After stage 1, right ventricular dilatation and qualitative dysfunction were associated with increased risk of transplant or death; whereas better tricuspid valve annular planar systolic excursion and a smaller left ventricle were associated with reduced mortality or transplant. There is substantial interstage right ventricular dilatation with concomitantly increased neoaortic and tricuspid regurgitation. Together our results emphasize worse right ventricular function, a larger left ventricle (thicker interventricular septum and larger cavity) at baseline and on followup and neoaortic valve regurgitation as risk factors for adverse outcomes. These parameters, together with clinical parameters, can augment the predictive value of echocardiography in hypoplastic left heart syndrome, potentially increasing its usefulness in prognostication, counseling, and management of this high-risk population.
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Echocardiography
There were 4 echocardiograms analyzed for each patient (1) the first full anatomic study after presentation, (2) before stage-2 surgery, closest to the date of routine cardiac catheterization for hemodynamic assessment before caval-pulmonary connection, (3) before stage-3 surgery (total caval-pulmonary connection), closest to the date of routine pre-Fontan cardiac catheterization for hemodynamic assessment, and (4) the last echocardiogram at time of data analysis or the last comprehensive echocardiogram before heart transplant or death. Echocardiography was performed using General Electric Vivid 7 (GE Healthcare, United States) or Philips iE33 (Philips Healthcare, Andover, MA) according to existing clinical protocols. Sedation was used as per the sedation protocol in The Hospital for Sick Children. Echocardiograms were performed under sedation using chloral hydrate for children aged 3 weeks to 3 years if it was deemed safe and appropriate for the child to receive sedation after review by the sedation nurse/anesthetic team. All echocardiograms were retrospectively analyzed offline for the purposes of this study with Syngo Dynamics Workstation (Version 5.1 Siemens AG, Erlangen, Germany) by a single investigator (Dr Son). RV enddiastolic area (EDA) and end-systolic area (ESA) were measured according to American Society of Echocardiography recommendations from the apical view and indexed to body surface area (BSA). 24 RV fractional area change (FAC) % was calculated. Qualitative RV function was graded as good, mildly decreased, moderately decreased, or severely decreased. Tricuspid valve annular plane systolic excursion (TAPSE) was measured in the apical view and z scores were calculated. 25 These z scores are based on normal hearts and not HLHS but are the reference values used by many studies to assess RV function. The RV sphericity index was measured from the apical view at end-diastole and calculated as the RV transverse (lateral) axis divided by its long-axis from base to apex. The severity of tricuspid valve regurgitation was graded qualitatively as none, trivial, mild, moderate, or severe and quantified using the regurgitant jet vena contracta indexed to body surface area.
1 Pulmonary or neoaortic regurgitation was qualitatively assessed and quantified by the ratio of the vena contracta width to pulmonary or neoaortic valve diameter. Interventricular septal length, its thickness 1-cm below the mitral valve annulus and LV length (mitral valve annulus level to apex of the LV cavity) were measured from apical views at end diastole. 7 Ascending aorta, left, and right PA dimensions were measured from parasternal views.
Clinical Events
Clinical events were extracted from review of the medical record as recorded by the clinical team as: cardiac (cardiogenic shock, cardiovascular instability, cardiac arrest, need for cardiopulmonary resuscitation with chest compressions, arrhythmia); gastrointestinal (necrotizing enterocolitis, hepatic dysfunction); respiratory (pneumonia, pulmonary vascular disease/pulmonary hypertension, apnea), infection (sepsis); renal (renal failure); metabolic (hypocalcemia, hypomagnesemia, jaundice); hematologic (anemia, coagulopathy); and neurological (seizures, altered consciousness, abnormal brain imaging instigated by a clinical event).
DATA AND STATISTICAL ANALYSIS Outcomes
The primary outcome for echo parameters was the time to death or heart transplant after initial surgery, right censored at stage-3 surgery. The secondary outcome was the time to death or transplant since the initial surgery, right censored at stage-2 surgery.
Descriptive Analysis
The data were described using descriptive statistics. Continuous variables were summarized in terms of medians and interquartile ranges, and between-group differences were assessed using Wilcoxon rank-sum test. Dichotomous and polychotomous variables were summarized as the frequency and proportions of patients, and between-group differences were assessed using Fisher exact tests.
For the primary outcome, the Kaplan-Meier method was first applied to assess the overall freedom from death/heart transplant. Furthermore, to account for the sequential surgical procedures, the primary outcome was analyzed using the model proposed by Prentice, Williams and Peterson (PWP) in describing the freedom from death/ transplant. 26 The PWP model assumed years since stage-1 surgery as the time scale and differentiated the mortality/transplant event depending on whether one received stage-2. For example, only the patients who received stage-2 were at risk for post-stage-2 mortality/transplant. This allows separate quantifications of stage-specific (base) hazard functions for mortality/transplant. Not only does the PWP model use the hierarchical nature of the surgical procedures, but it is sufficiently flexible to accommodate time-varying risk factors, such as echo parameters. In addition to the PWP model with the year since stage-1 surgery, a gap-time analysis, timescale of which was a year since the last surgery, was conducted. In this gap-time analysis, we also assessed the risk of mortality/ transplant associated with the time-dependent surgery stage. The significance of the time-dependent surgery stage was evaluated using Wald tests with robust SEs.
Baseline Analysis
Given that there were patients who may undergo heart transplant or die immediately after stage-1 surgery, univariable proportional hazard regression was applied to assess the association between the primary outcome and baseline clinical characteristics. The association was quantified by hazard ratios (HRs). Confidence intervals (CIs) and P values were estimated using Wald statistics. Clinical characteristics that were not available for >50% of the patients were excluded from the analysis. Continuous characteristics with missing values were imputed to the observed means.
Change in Echo Parameters After Each Surgical Stage
Prepost analysis was conducted at each surgical stage. Continuous echo parameters were summarized as mean and SD before and after the surgical stage. Among patients with both pre-and poststage echo's, the mean difference (post−pre) was assessed with the 95% confidence intervals (CIs) and the corresponding P value calculated using paired t tests. Qualitative echo parameters (eg, subjective RV function) were summarized as frequencies before and after the surgery and prepost changes assessed using Bowker tests.
Exploratory Time-Trend Analysis
Overall time-dependent trends in echo parameters since the first echo were explored graphically. A nonparametric smooth time-trend stratified by patient survival status was estimated using the LOESS method (Locally Weighted Scatter-plot Smoother).
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Risk Factor Analysis for Time-to-Event Outcomes
To determine the associations between the echo characteristics and outcomes, univariable regression analysis was conducted using the PWP model among those with postsurgery clinical characteristics. For the primary outcome, the postsurgery clinical characteristics included those at baseline, as well as between stage-1 and stage-3 surgery. For the secondary outcome, they included the baseline echo characteristics and those between stage-1 and stage-2 surgery.
In determining echo characteristics associated with outcome variables, candidate risk factors were screened based on 3-criteria-the proportion of missing values, the number of patients (for dichotomous and polychotomous variables), and the definitions of variables. Characteristics with a considerable amount of missing (eg, >50%) or with a small number of patients (eg, ≤10) were excluded from further analysis. In addition, variables with interdependent definitions were scrutinized and selectively considered as candidate risk factors. Variable selection was then conducted using the stepwise strategy recommended by Collett. 28 To assess the performance of the variable selection strategy, bootstrapping was applied to assess its performance and reliability. Specifically, 500 bootstrap samples by patient identifiers were constructed, and the aforementioned variable selection strategy was applied for each bootstrap sample. Risk factor reliability was calculated as the proportion of the bootstrap models containing the risk factor. The risk factor in the final multivariable models must have achieved a ≥50% reliability and statistical significance. Statistical analysis used SAS v9.4 (SAS Institute, North Carolina). The study was approved by the institutional research ethics board.
RESULTS
One hundred and seventeen infants with HLHS were identified from the database. Fifty patients were excluded because of atrial isomerism (heterotaxy), total anomalous pulmonary venous drainage, unbalanced atrioventricular septal defect, misclassification as HLHS or died/were transplanted before stage 1. Consequently, a total of 67 children with HLHS who underwent stage-1 surgery were included. Among our cohort the surgeries were performed on an average, mean (SD) of 6.5 (4.4) days for stage 1, 173 (420) days for stage 2, and 1121 (198) days for stage 3 in keeping with recognized timings for palliative surgeries in this population. Thirty-two (48%), 28 (41%), and 7 (10%) patients received a BlalockTaussig shunt, a hybrid procedure, and an RV-PA conduit, at stage 1, respectively. Table 1 shows that patients were predominately male (75%). The median (interquartile range) gestational age was 39 (38) (39) (40) weeks. Forty-eight (72%) patients were diagnosed with aortic atresia, 19 (28%) aortic stenosis, 27 (40%) mitral atresia, and 40 (60%) mitral stenosis. Forty-five (67%) patients had prenatal diagnosis, and 7 (10%) patients had a diagnosed extracardiac malformation.
Survival Analysis
Among the 67 patients who underwent stage-1 surgery, 8 (12%) received cardiac transplant and 24 (36%) died at the end of follow-up. From those who received a transplant or died 12 were at stage 1, 11 were between stage 1 and stage 2, 5 were at stage 2, and 4 were between stage 2 and stage 3. Figure 1 shows the Kaplan-Meier estimated freedom from death and heart transplant. The estimated 10-week, 20-week, and 1-year survival rates after stage-1 surgery were 78% (66-86), 69% (56-78), and 54% (41-65), respectively.
After stage-1 surgery, 44 patients underwent subsequent surgery. Twenty-three (34%) patients underwent stage-2 surgery, 21 (31%) underwent both stage-2 and 3 procedures. Six (9%) patients underwent cardiac transplant before stage-2 surgery and 2 (3%) patients underwent transplant after stage-2 surgery. Seventeen (25%) patients died before stage-2 surgery and 7 (10%) patients died after stage-2 surgery. Figure 1 shows freedom from death or transplant using the PWP model. The red curve shows the freedom from death or transplant, right censored at stage-2, for all 67 patients. The blue curve shows, among those who underwent stage-2 surgery, the freedom from death or transplant, right censored at stage 3. Figure 2 shows the freedom from death or transplant using time to death or transplant from the previous operation. The red curve in Figure 2 is identical to its counterpart in Figure 1 . However, the blue curve in Figure 2 differs from Figure 1 in that the PWP model in Figure 1 considers the sequential nature of the operation by accounting for the timing of stage-2 operation. For example, a patient who underwent stage-2 operation at week 12 was not at risk for post-stage-2 mortality or transplant until week 12, whereas the analysis in Figure 2 does not consider the timing and assumes all patients who survived and underwent stage-2 operation were at risk for post-stage 2 mortality and transplant at the same time.
Risk Factor Analysis for the Primary Outcome (Time to Death/Transplant Since Stage 1, Right Censored at Stage 3)
All patients underwent echocardiography before stage-1 surgery (Table 2) . Table 3 shows results of univariable proportional hazard modeling for baseline (prestage 1) clinical and echo characteristics on the primary outcome. The following baseline clinical candidate risk factors were included in the PWP model: Male gender, gestational age at birth, APGAR scores at 1 and 5 minutes, weight at time of stage-1 surgery, type of stage-1 surgery, HLHS morphological subtype (aortic atresia versus aortic stenosis; mitral atresia versus mitral stenosis), prenatal diagnosis, extracardiac malformation, and major clinical events before stage-1 surgery (cardiac event, shock). Other clinical factors such as weight, hybrid approach, and aortic atresia although significant did not meet sufficient reliability and criteria to be included in the PWP model.
The following baseline echo parameters were entered into the model: RVEDA, RVESA, LVEDA, and LVESA (all indexed to BSA), FAC%, septal length, interventricular septal thickness, TAPSE z score, RV sphericity, qualitative RV function (good versus any degree of decreased function), tricuspid valve diameter z score, qualitative grading of tricuspid regurgitation (none versus moderate-or-severe), tricuspid regurgitation vena contracta indexed to BSA, mitral valve diameter z score, diameter of pulmonary or neoaortic valve, qualitative grading of pulmonary and neoaortic regurgitation (none versus trivial versus moderate-to-severe), proportion of vena contracta to pulmonary or neoaortic valve BT indicates Blalock-Taussig; PAB, pulmonary artery band; and RV-PA conduit, right ventricle to pulmonary artery conduit. diameter, narrowest diameter of the left and right PA, and ascending aorta diameter at birth.
Postsurgical echo parameters entered into the model were the same as listed above.
The final multivariable model identified 2 baseline and 5 postsurgery clinical or echo characteristics that were associated with the primary outcome ( 
Changes in Echo Parameters
Before and After Stage-1, 2, and 3 Table 6 summarizes the changes in the echo parameters before and after stage-1 surgery. Notable parameters with significant changes included indexed RVEDA and RVESA, interventricular septal thickness, pulmonary/ neoaortic regurgitation vena contracta, pulmonary/ neoaortic valve diameter, qualitative grading of pulmonary/neoaortic valve regurgitation, TAPSE z score, BSA-indexed tricuspid regurgitation vena contracta and qualitative grading of tricuspid valve regurgitation (P=0.04). 
Exploratory Time-Trend Analysis
The plots in Figures 3 and 4 show a sample of echo parameters over time, since the first echo, for each patient; whereas, overall time trends, stratified by the survival status at the end of the follow-up, were estimated and superimposed. For example, indexed RVEDA had a steady decreasing trend in patients who survived without transplant during the follow-up period and an increasing trend in patients who received a transplant or died. This suggests that patients with a higher rate of increase in indexed RVEDA were at higher risk of mortality or transplant. Similar trends were seen for indexed RVESA, RV FAC%, TAPSE z score and severity of tricuspid regurgitation, which worsened over time in patients who were transplanted or died in comparison to transplant-free survivors.
DISCUSSION
In the current study, we undertook to perform a comprehensive, serial evaluation of widely used and available echocardiographic parameters, in the context of the clinical status, in relation to HLHS outcomes through staged palliation.
The major findings of our study are (1) at presentation (before stage 1) increased interventricular septal thickness was associated with elevated risk of transplant or death to stage 2 and stage 3, and a larger LV was associated with worse transplant-free survival to stage 2. (2) A better TAPSE z score at baseline was associated with reduced risk of transplant or death. (3) After stage-1, RV dilatation and qualitative dysfunction were associated with increased risk of transplant or death; whereas better TAPSE and a smaller LV were associated with reduced mortality or transplant. (4) There is substantial interstage RV dilatation with concomitantly increased neoaortic and tricuspid regurgitation.
Taken together our results emphasize worse RV function, a larger LV (thicker interventricular septum and larger cavity) at baseline and on follow-up and BSA indicates body surface area; BT, Blalock-Taussig; fractional area change; LVEDA, left ventricular end-diastolic area; LVESA, left ventricular end-systolic area; RV-PA conduit, right ventricle to pulmonary artery conduit; RVEDA, right ventricular end-diastolic area; RVESA, right ventricular end-systolic area; TAPSE, tricuspid valve annular planar systolic excursion; and TR, tricuspid regurgitation. 
Survival Analysis
In our study, the survival rate to the Fontan operation was 58% with the highest mortality occurring around the time of initial surgery and between stage 1 and stage 2. These results are consistent with previous data investigating outcomes in children with HLHS, 31, 32 although some institutions have reported better outcomes.
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RV Function
RV dysfunction is well recognized as a risk factor for poor outcome in HLHS. However, its impact from baseline through the various surgical stages has not been well delineated. Similar to the baseline characteristics and echocardiographic findings, we found that RV dysfunction, both qualitatively assessed, as well as quantitatively measured (TAPSE, FAC, RVEDA), was associated with poor outcomes, particularly between stage-1 and stage-2 surgery. This suggests that assessment of these parameters at baseline and during continued monitoring can play a role in predicting outcomes and deciding on management. Although RV remodeling and dysfunction are difficult to assess because of its complex structure, 34 our results suggest that relatively simple qualitative and quantitative markers such as RV dimensions, TAPSE, and FAC% have prognostic value. Indeed, quantitative measures such as FAC and TAPSE have been increasingly used in clinical assessment of RV function and have been shown to be useful in HLHS. 5, 35 In the current study, we found that at baseline and after stage 1, a better TAPSE z score was associated with reduced risk of death and transplant; and that after stage 1, indexed RVESA, FAC%, and abnormal qualitative RV function were associated with increased risk of transplant or death. This RV function stratification at baseline around the time of the initial operation may be beneficial in guiding management options and help to predict outcomes after surgical intervention. 13 Similar to our findings, other studies investigating TAPSE and FAC around the time of the Norwood procedure and the effect of different shunt types on RV physiology, 36 noted that reduced TAPSE and FAC predicted increased mortality or transplantation. 37 Our finding that higher indexed RVESA was associated with worse outcome is wimportant as RVESA speaks to RV contrac- tile function and remodeling. Our results also highlight the importance of qualitative assessment of RV function in HLHS; as qualitative RV dysfunction was associated with increased interstage mortality. This result is important, as although there are important and well-known limitations in qualitative assessment of RV dysfunction, 34 even among experienced observers, it is widely used in clinical practice and an important component of RV functional assessment.
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LV and Septal Characteristics
The interventricular septum plays a crucial role in RV and LV function. 39 Our results highlight a possibly important role for the interventricular septum in HLHS, either because of the lack of a well-functioning septum itself; or perhaps for other parameters for which the interventricular septal thickness is a surrogate marker such as the anatomic subtype (eg, a thick septum associated with mitral stenosis/aortic atresia). Interestingly, we found at baseline that increased interventricular septal thickness was associated with elevated risk of transplant-free mortality. These results are in keeping with previous results from our institution in which Walsh et al 7 found that septal hypertrophy adversely affected the outcome of HLHS patients. Our results before stage 1, together with those of Walsh et al 7 suggest that intrinsic morphological and physiological characteristics may be strong determining factors of the outcomes in HLHS, regardless of the surgical strategy used at stage 1. This is also in keeping with recent work from our institution comparing RV function between the Norwood and hybrid procedures at stage 1. 5 It has been postulated previously that the interventricular septal thickness may be related to abnormal coronary artery perfusion with a disproportionate amount of blood flow being diverted to the hypertrophied septum resulting in decreased coronary perfusion to the RV. 40 Although we carefully attempted to control for co-related factors, we cannot exclude that septal thickness is a surrogate marker of mitral stenosis/aortic atresia. This morphological HLHS subtype is typically characterized by a thick interventricular septum, small LV cavity, and worse outcome. [8] [9] [10] Some authors have suggested that the underlying pathophysiology is the presence of LV coronary sinusoids that, when present, are typically associated with a mitral stenosis/aortic atresia phenotype. 10 A thicker septum, which in HLHS is largely noncontractile, and presence of a LV cavity, may also be associated with differences in mechanical contraction patterns around the tricuspid annulus with higher RV inefficiency and increased tricuspid regurgitation. 41 Thus, although BSA indicates body surface area; BT, Blalock-Taussig; FAC, fractional area change; LVEDA, left ventricular end-diastolic area; LVESA, left ventricular end-systolic area; PAB, pulmonary artery band; RV-PA conduit, right ventricle to pulmonary artery conduit; RVEDA, right ventricular end-diastolic area; RVESA, right ventricular end-systolic area; TAPSE, tricuspid valve annular planar systolic excursion; and TR, tricuspid regurgitation. 
RV Dilatation and Function Over Time
We compared echo parameters before and after each surgical stage to quantify the impact of the surgical approach on RV function and used a sophisticated statistical approach to assess whether changes in these markers are predictive of outcomes. Several studies have highlighted tricuspid regurgitation as a predictor of poor outcomes. 16, 42 Our univariable analysis also suggest that neoaortic regurgitation predicted outcomes. Just as chronic aortic insufficiency can lead to LV remodeling, dysfunction, and death in a normal biventricular circulation, 43, 44 chronic neo-aortic insufficiency (AI) poses an added volume load on an already compromised RV. In addition, diastolic runoff may impact diastolic coronary flow and myocardial perfusion pressure, exacerbating RV ischemia. Neo-AI may also compromise cardiac output, already precarious in many HLHS patients. Moreover, a dilated RV has been shown to be associated with arrhythmias and poor diastolic function. 
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Trends Over Time
Our graphing of trends over time are consistent with parameters of RV remodeling and function as being associated with adverse outcomes, with substantial differences observed between survivors and nonsurvivors. This suggests that risk factors at baseline or at interstage assessment continue to be useful when serially evaluating patients over time. In this regard, our article adds important data to existing literature and stresses the importance of serial assessment using the parameters detailed below. Although noninvasive evaluation during the 3-staged surgery remains nonstandardized with different approaches across physicians and institutions, 46 qualitative assessment of RV function, FAC%, TAPSE, tricuspid regurgitation, neo-AI, and tricuspid and neoaortic valve size seem to be useful tools in predicting those who develop poor outcomes with increased risk of death or transplantation. 15 A lack of improvement in parameters of RV remodeling and dysfunction seems to be particularly concerning. This needs to be confirmed in prospective studies and may aid in guiding management in high-risk patients earlier in the disease course.
Study Limitations
The retrospective nature of this study brings with its inherent limitations. Echocardiograms were obtained for clinical purposes and were retrospectively analyzed. Thus, image quality was not optimal in all studies. Although we attempted to carefully control for co-related factors in the risk analysis, many factors are intrinsically linked. We did not analyze parameters of myocardial performance such as strain. This was partly because of the retrospective nature of the study as detailed above and because the aim of this study was to investigate conventional parameters that are widely utilized or available in clinical practice and form part of current pediatric echo recommendations. 24 Future analysis of RV strain in a similarly designed analysis may provide additional data. Likewise, RV volumes and function measured by 3-dimensional echocardiography or analyzed using automated measurements may be beneficial. 47, 48 We did not analyze a healthy control population, as neither systemic LV or subpulmonary RV function accurately control for HLHS morphology, physiology, function, or loading conditions.
There are also some methodological limitations. Candidate risk factors were selected a priori from a pool of baseline patient characteristics and serial echo parameters based on the clinical relevance and data availability. Given the number of patients, some important risk factors may be excluded as a result of rare medical events at baseline (eg, infections and shocks) and echo parameters infrequently measured in stan- BSA indicates body surface area; FAC, fractional area change; LVEDA, left ventricular end-diastolic area; LVESA, left ventricular end-systolic area; RVEDA, right ventricular end-diastolic area; RVESA, right ventricular end-systolic area; TAPSE, tricuspid valve annular planar systolic excursion; and TR, tricuspid regurgitation.
dard clinical settings. Second, mean imputation was applied to address missing values in selected baseline patient characteristics. Although mean imputation reduced the uncertainty in the data, the majority of baseline patient characteristics had a missing proportion around 10%.
Furthermore, the number of candidate risk factors considered in the risk factor analysis was relatively large compared with the number of patients. In this situation, we recognized and were concerned about potential inflated type 1 error and overfitting. We attempted to alleviate this concern using bootstrapping by quantifying the validity of a selected risk factor in bootstrap samples. We considered bootstrap samples as pseudodata, generated under a similar clinical setting, and apply the same variable selection strategy to them. Not only can we better understand the performance of the variable selection strategy outlined previously, but we were able to assess how consistently a risk factor was selected by calculating the bootstrapped proportion of selected echo parameters among all bootstrap samples. The final multivariable hazard regression model included all candidate risk factors that were both reliable and statistically significant.
Although this resampling strategy could reduce, but not completely remove, some falsely selected risk factors, further studies are required to validate the study findings in light of these limitations.
Our population included patients with different morphological subtypes and who underwent different approaches at stage 1 which may impact ventricular shape and function. 49, 50 Analyzing these aspects would provide helpful data and requires separate study in a larger cohort.
Conclusions
In conclusion, widely available echocardiographic parameters at presentation, as well as during serial follow-up, are a marker for transplantation or death in infants and children with HLHS which should be used in conjunction with clinical parameters. In addition to RV size and function, our data highlight interventricular septal thickness, LV size, and neo-AI as important markers of outcome. These parameters, together with clinical parameters, can augment the predictive value of echocardiography in HLHS; potentially increasing its usefulness in prognostication, counseling, and management of this high-risk population. 
